Mika Hoshino
Overview
Explore the profile of Mika Hoshino including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
30
Citations
409
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Muto S, Enta A, Maruya Y, Inomata S, Yamaguchi H, Mine H, et al.
Biomedicines
. 2023 Jan;
11(1).
PMID: 36672698
Lung cancer is the leading cause of cancer-related deaths worldwide. The standard of care for advanced non-small-cell lung cancer (NSCLC) without driver-gene mutations is a combination of an anti-PD-1/PD-L1 antibody...
2.
Muto S, Inomata S, Yamaguchi H, Mine H, Takagi H, Watanabe M, et al.
Gan To Kagaku Ryoho
. 2022 Sep;
49(9):947-949.
PMID: 36156012
Recently, β-catenin mediated immune escape mechanism has been reported in several cancers. We investigated whether β-catenin is associated with resistance to immune checkpoint inhibitor therapy in non-small cell lung cancer....
3.
Muto S, Inomata S, Yamaguchi H, Mine H, Takagi H, Watanabe M, et al.
Gan To Kagaku Ryoho
. 2022 Sep;
49(9):928-931.
PMID: 36156007
Although the indications for immune checkpoint inhibitors are expanding rapidly, the disease will eventually progress in many patients. Elucidating and overcoming the resistant mechanisms to immune checkpoint inhibitors is a...
4.
Muto S, Inomata S, Yamaguchi H, Mine H, Takagi H, Ozaki Y, et al.
Anticancer Res
. 2021 Dec;
41(12):6267-6272.
PMID: 34848482
Background/aim: Treatments containing ipilimumab have shown a good outcome in patients with non-small cell lung cancer (NSCLC) regardless of the PD-L1 tumor proportion score (TPS). However, the association between PD-L1...
5.
Fukuhara M, Muto S, Inomata S, Yamaguchi H, Mine H, Takagi H, et al.
Cancer Immunol Immunother
. 2021 Oct;
71(5):1129-1137.
PMID: 34596720
Introduction: The presence of tertiary lymphoid structure (TLS) in tumor tissues has been reported to be a factor associated with a good prognosis in several types of cancers. However, the...
6.
Muto S, Ozaki Y, Yamaguchi H, Mine H, Takagi H, Watanabe M, et al.
Oncol Lett
. 2021 Feb;
21(3):203.
PMID: 33574942
β-catenin expression by tumor cells suppressed dendritic cell recruitment to the tumor microenvironment in a melanoma model, resulting in fewer tumor-infiltrating lymphocytes. Immunohistochemistry was used in the present study to...
7.
Takagi H, Zhao S, Muto S, Yokouchi H, Nishihara H, Harada T, et al.
Lung Cancer
. 2021 Jan;
153:134-142.
PMID: 33508526
Objectives: Delta-like 1 homolog (DLK1) is a non-canonical Notch ligand known to be expressed in several cancers but whose role in lung cancer is not yet fully understood. We sought...
8.
Muto S, Yamaguchi H, Mine H, Takagi H, Ozaki Y, Watanabe M, et al.
Gan To Kagaku Ryoho
. 2020 Nov;
47(9):1287-1291.
PMID: 33130685
There have been many reports on the association between tumor infiltrating lymphocytes and cancer prognosis. It is known that tumor infiltrating lymphocytes contain not only cytotoxic T lymphocytes but also...
9.
Yamaura T, Muto S, Mine H, Takagi H, Watanabe M, Ozaki Y, et al.
Oncol Lett
. 2020 May;
19(6):4169-4176.
PMID: 32391110
Epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) are an approved first-line therapy against unresectable or advanced non-small cell lung cancer (NSCLC) harboring gene activating mutations. However, the majority of...
10.
Ozaki Y, Muto S, Takagi H, Watanabe M, Inoue T, Fukuhara M, et al.
Cancer Immunol Immunother
. 2019 Dec;
69(1):127-134.
PMID: 31807880
Cancer treatment using immune checkpoint inhibitors is widely used, although biomarkers predictive of response are not well established. However, both the expressions of programmed cell death ligand 1 (PD-L1) and...